Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up3.020 +0.010 (+0.332%)
Others

19/06/2018 17:25

Sino Biopharm's "Debaining" drug gets registration approval

[ET Net News Agency, 19 June 2018] Sino Biopharmaceutical (01177) said Lidocaine
Cataplasm (Product name "Debaining"), a drug developed by its subsidiary Beijing Tide
Pharmaceutical, has obtained approval for drug registration by the National Drug
Administration of the People's Republic of China.
In addition, the product has obtained a new drug certificate with a four-year monitoring
period. This marks the upcoming official launch of the first topical therapeutic patch in
the field of neuropathic pain in China, which fills the gap in the PRC.
Lidocaine Cataplasm is used to treat postherpetic neuralgia, and is listed as a
first-class recommended drug in clinical guidelines in the United States, Europe, China
and other places. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.